Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Stem Cells Translational Medicine|May 17, 2014
Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiationLara Lacerda, Jay P Reddy, Diane Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2013
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypesHiroko Masuda, Keith A Baggerly, Ying Wang, et al.
BMC Cancer|May 20, 2020
Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBCToshiaki Iwase, Kenichi Harano, Hiroko Masuda, et al.
Molecular Cancer Therapeutics|October 8, 2015
Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B KinasesKazuharu Kai, Kimie Kondo, Xiaoping Wang, et al.
Scientific Reports|December 4, 2020
BRCAness as a prognostic indicator in patients with early breast cancerLei Liu, Yuki Matsunaga, Junji Tsurutani, et al.
The Oncologist|February 1, 2020
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without TrastuzumabTakahiro Kogawa, Takeo Fujii, Jimin Wu, et al.
Breast Cancer Research and Treatment|April 19, 2017
Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expressionMonica E Reyes, Takeo Fujii, Daniel Branstetter, et al.
Journal of Cancer|March 14, 2015
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast CancerTakahiro Kogawa, Tamer M Fouad, Caimiao Wei, et al.
Breast Cancer Research : BCR|January 10, 2015
Circulating tumor cells in newly diagnosed inflammatory breast cancerMichal Mego, Antonio Giordano, Ugo De Giorgi, et al.
BMJ Open|May 13, 2026
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10)Yukinori Ozaki, Shohei Koyama, Satoshi Morita, et al.
Pageof 6